Bioterrorism and Patent Rights: "Compulsory Licensure" and the Case of Cipro

Discusses ethical and policy issues relating to the US government's decision not to override Bayer's patent on Cipro in response to increased demands for the drug in the wake of the anthrax bioterrorism scare; includes 9 open peer commentaries. Trade-Related Intellectual Property Rights Ag...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of bioethics 2002, Vol.2 (3), p.29-39
Hauptverfasser:	Resnik, David B., De Ville, Kenneth A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anthrax Anthrax - drug therapy Anthrax - prevention & control Bioethics Bioterrorism Cipro Ciprofloxacin - supply & distribution Ciprofloxacin - therapeutic use Compensation and Redress - legislation & jurisprudence Drug Industry - economics Drug Industry - legislation & jurisprudence Ethical Analysis Ethical Theory Federal Government Freedom Humans Intellectual Property International aspects Internationality Legal aspects Licensure - legislation & jurisprudence Medical sector Patents as Topic - ethics Patents as Topic - legislation & jurisprudence Pharmaceutical Companies Pharmaceutical industry Pharmaceutical Preparations - economics Pharmaceutical Preparations - supply & distribution Private Sector Property, Intellectual Public Health Public Policy Public Sector Research Support as Topic Social Justice Time Factors Treaties United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Discusses ethical and policy issues relating to the US government's decision not to override Bayer's patent on Cipro in response to increased demands for the drug in the wake of the anthrax bioterrorism scare; includes 9 open peer commentaries. Trade-Related Intellectual Property Rights Agreement (TRIPS).
ISSN:	1526-5161 1536-0075
DOI:	10.1162/152651602760250084